Cyclin-dependent kinase 2 phosphorylates S/T-P sites in the hepadnavirus core protein C-terminal domain and is incorporated into viral capsids

Journal of Virology

Volumn 86, Issue 22, 2012, Pages 12237-12250

  Ludgate, Laurie ^a   Ning, Xiaojun ^a   Nguyen, David H ^a,b   Adams, Christina ^a   Mentzer, Laura ^a   Hu, Jianming ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORE PROTEIN; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 2 INHIBITOR; HYBRID PROTEIN; PROLINE; SERINE; THREONINE;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL LYSATE; CONTROLLED STUDY; DNA PACKAGING; DUCK HEPATITIS B VIRUS; EMBRYO; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HEPADNAVIRUS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; STRUCTURE ACTIVITY RELATION; VIRUS CAPSID; VIRUS REPLICATION; WESTERN BLOTTING;

AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; CAPSID; CYCLIN-DEPENDENT KINASE 2; DUCKS; HEK293 CELLS; HEP G2 CELLS; HEPADNAVIRIDAE; HEPATITIS B VIRUS; HUMANS; INHIBITORY CONCENTRATION 50; MOLECULAR SEQUENCE DATA; PEPTIDE HYDROLASES; PHOSPHORYLATION; PHOSPHOTRANSFERASES; PROTEIN STRUCTURE, TERTIARY; RABBITS; SEQUENCE HOMOLOGY, AMINO ACID; VIRAL CORE PROTEINS;

DUCK HEPATITIS B VIRUS; HEPADNAVIRIDAE; HEPATITIS B VIRUS; MAMMALIA; MIRIDAE;

EID: 84869133121     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01218-12     Document Type: Article

References (71)

1. Albin C, Robinson WS. 1980. Protein kinase activity in hepatitis B virus. J. Virol. 34:297-302.
2. Alessi F, et al. 1998. The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity. Exp. Cell Res. 245:8-18.
3. Barrasa MI, Guo JT, Saputelli J, Mason WS, Seeger C. 2001. Does a cdc2 kinase-like recognition motif on the core protein of hepadnaviruses regulate assembly and disintegration of capsids? J. Virol. 75:2024-2028.
4. Basagoudanavar SH, Perlman DH, Hu J. 2007. Regulation of hepadnavirus reverse transcription by dynamic nucleocapsid phosphorylation. J. Virol. 81:1641-1649.
5. Benn J, Schneider RJ. 1995. Hepatitis B virus HBx protein deregulates cell cycle checkpoint controls. Proc. Natl. Acad. Sci. U. S. A. 92:11215-11219.
6. Bouchard M, Giannakopoulos S, Wang EH, Tanese N, Schneider RJ. 2001. Hepatitis B virus HBx protein activation of cyclin A-cyclindependent kinase 2 complexes and G1 transit via a Src kinase pathway. J. Virol. 75:4247-4257.
7. Brooks EE, et al. 1997. CVT-313, a specific and potent inhibitor of CDK2 that prevents neointimal proliferation. J. Biol. Chem. 272:29207-29211.
8. Chen C, Wang JC, Zlotnick A. 2011. A kinase chaperones hepatitis B virus capsid assembly and captures capsid dynamics in vitro. PLoS Pathog. 7:e1002388. doi:10.1371/journal.ppat.1002388.
9. Crowther RA, et al. 1994. Three-dimensional structure of hepatitis B virus core particles determined by electron cryomicroscopy. Cell 77:943-950.
10. Daub H, et al. 2002. Identification of SRPK1 and SRPK2 as the major cellular protein kinases phosphorylating hepatitis B virus core protein. J. Virol. 76:8124-8137.
11. Davies SP, Reddy H, Caivano M, Cohen P. 2000. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351:95-105.
12. Duclos-Vallee JC, Capel F, Mabit H, Petit MA. 1998. Phosphorylation of the hepatitis B virus core protein by glyceraldehyde-3-phosphate dehydrogenase protein kinase activity. J. Gen. Virol. 79(Pt 7):1665-1670.
13. Fallows DA, Goff SP. 1995. Mutations in the epsilon sequences of human hepatitis B virus affect both RNA encapsidation and reverse transcription. J. Virol. 69:3067-3073.
14. Gao W, Hu J. 2007. Formation of hepatitis B virus covalently closed circular DNA: removal of genome-linked protein. J. Virol. 81:6164-6174.
15. Gazina EV, Fielding JE, Lin B, Anderson DA. 2000. Core protein phosphorylation modulates pregenomic RNA encapsidation to different extents in human and duck hepatitis B viruses. J. Virol. 74:4721-4728.
16. Gearhart TL, Bouchard MJ. 2010. Replication of the hepatitis B virus requires a calcium-dependent HBx-induced G1 phase arrest of hepatocytes. Virology 407:14-25.
17. Gearhart TL, Bouchard MJ. 2010. The hepatitis B virus X protein modulates hepatocyte proliferation pathways to stimulate viral replication. J. Virol. 84:2675-2686.
18. Gerlich WH, Goldmann U, Muller R, Stibbe W, Wolff W. 1982. Specificity and localization of the hepatitis B virus-associated protein kinase. J. Virol. 42:761-766.
19. Gschwendt M, et al. 1996. Inhibition of protein kinase C mu by various inhibitors. Differentiation from protein kinase c isoenzymes. FEBS Lett. 392:77-80.
20. Hidaka H, Inagaki M, Kawamoto S, Sasaki Y. 1984. Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C. Biochemistry 23:5036-5041.
21. Hu J, Anselmo D. 2000. In vitro reconstitution of a functional duck hepatitis B virus reverse transcriptase: posttranslational activation by Hsp90. J. Virol. 74:11447-11455.
22. Jilbert AR, et al. 1992. Rapid resolution of duck hepatitis B virus infections occurs after massive hepatocellular involvement. J. Virol. 66:1377-1388.
23. Kann M, Gerlich WH. 1994. Effect of core protein phosphorylation by protein kinase C on encapsidation of RNA within core particles of hepatitis B virus. J. Virol. 68:7993-8000.
24. Kann M, Sodeik B, Vlachou A, Gerlich WH, Helenius A. 1999. Phosphorylation-dependent binding of hepatitis B virus core particles to the nuclear pore complex. J. Cell Biol. 145:45-55.
25. Kann M, Thomssen R, Kochel HG, Gerlich WH. 1993. Characterization of the endogenous protein kinase activity of the hepatitis B virus. Arch. Virol. Suppl. 8:53-62.
26. Kau JH, Ting LP. 1998. Phosphorylation of the core protein of hepatitis B virus by a 46-kilodalton serine kinase. J. Virol. 72:3796-3803.
27. Kore AR, et al. 2009. Synthesis and application of MeOSuc-Ala-Ala-Pro-Phe-CH2Cl as potent proteinase K inhibitor. Bioorg. Med. Chem. Lett. 19:1296-1300.
28. Krasinska L, Cot E, Fisher D. 2008. Selective chemical inhibition as a tool to study Cdk1 and Cdk2 functions in the cell cycle. Cell Cycle 7:1702-1708.
29. Lan YT, Li J, Liao W, Ou J. 1999. Roles of the three major phosphorylation sites of hepatitis B virus core protein in viral replication. Virology 259:342-348.
30. Lanford RE, Notvall L. 1990. Expression of hepatitis B virus core and precore antigens in insect cells and characterization of a core-associated kinase activity. Virology 176:222-233.
31. Lewellyn EB, Loeb DD. 2011. Serine phosphoacceptor sites within the core protein of hepatitis B virus contribute to genome replication pleiotropically. PLoS One 6:e17202. doi:10.1371/journal.pone.0017202.
32. Liao W, Ou JH. 1995. Phosphorylation and nuclear localization of the hepatitis B virus core protein: significance of serine in the three repeated SPRRR motifs. J. Virol. 69:1025-1029.
33. Ludgate L, Adams C, Hu J. 2011. Phosphorylation state-dependent interactions of hepadnavirus core protein with host factors. PLoS One 6:e29566. doi:10.1371/journal.pone.0029566.
34. Mabit H, Breiner KM, Knaust A, Zachmann-Brand B, Schaller H. 2001. Signals for bidirectional nucleocytoplasmic transport in the duck hepatitis B virus capsid protein. J. Virol. 75:1968-1977.
35. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. 2002. The protein kinase complement of the human genome. Science 298:1912-1934.
36. Meijer L, Bettayeb K, Galons H. 2007. (R)-Roscovitine (CYC202, Seliciclib), p 187-226. In Smith PJ, YueEW(ed), Inhibitors of cyclin-dependent kinases as anti-tumor agents. CRC Press, Boca Raton, FL.
37. Montagnoli A, et al. 2008. A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity. Nat. Chem. Biol. 4:357-365.
38. Mukherji A, Janbandhu VC, Kumar V. 2007. HBx-dependent cell cycle deregulation involves interaction with cyclin E/A-cdk2 complex and destabilization of p27Kip1. Biochem. J. 401:247-256.
39. Nguyen DH, Hu J. 2008. Reverse transcriptase-and RNA packaging signal-dependent incorporation of APOBEC3G into hepatitis B virus nucleocapsids. J. Virol. 82:6852-6861.
40. Ning X, et al. 2011. Secretion of genome-free hepatitis B virus-single strand blocking model for virion morphogenesis of para-retrovirus. PLoS Pathog. 7:e1002255. doi:10.1371/journal.ppat.1002255.
41. Nishikawa K, Toker A, Johannes FJ, Songyang Z, Cantley LC. 1997. Determination of the specific substrate sequence motifs of protein kinase C isozymes. J. Biol. Chem. 272:952-960.
42. Ozer A, et al. 1996. Effect of hepatocyte proliferation and cellular DNA synthesis on hepatitis B virus replication. Gastroenterology 110:1519-1528.
43. Perlman DH, Berg EA, O'Connor BP, Costello CE, Hu J. 2005. Reversetranscription-associated dephosphorylation of hepadnavirus nucleocapsids. Proc. Natl. Acad. Sci. U. S. A. 102:9020-9025.
44. Pinna LA, Ruzzene M. 1996. How do protein kinases recognize their substrates? Biochim. Biophys. Acta 1314:191-225.
45. Porterfield JZ, et al. 2010. Full-length hepatitis B virus core protein packages viral and heterologous RNA with similarly high levels of cooperativity. J. Virol. 84:7174-7184.
46. Pugh J, Zweidler A, Summers J. 1989. Characterization of the major duck hepatitis B virus core particle protein. J. Virol. 63:1371-1376.
47. Qatsha KA, Rudolph C, Marme D, Schachtele C, May WS. 1993. Go 6976, a selective inhibitor of protein kinase C, is a potent antagonist of human immunodeficiency virus 1 induction from latent/low-levelproducing producing reservoir cells in vitro. Proc. Natl. Acad. Sci. U. S. A. 90:4674-4678.
48. Rabe B, et al. 2009. Nuclear entry of hepatitis B virus capsids involves disintegration to protein dimers followed by nuclear reassociation to capsids. PLoS Pathog. 5:e1000563. doi:10.1371/journal.ppat.1000563.
49. Rickert P, Corden JL, Lees E. 1999. Cyclin C/CDK8 and cyclin H/CDK7/ p36 are biochemically distinct CTD kinases. Oncogene 18:1093-1102.
50. Scaglioni PP, Melegari M, Wands JR. 1997. Posttranscriptional regulation of hepatitis B virus replication by the precore protein. J. Virol. 71:345-353.
51. Schlicht HJ, Bartenschlager R, Schaller H. 1989. The duck hepatitis B virus core protein contains a highly phosphorylated C terminus that is essential for replication but not for RNA packaging. J. Virol. 63:2995-3000.
52. Seeger C, Mason WS, Zoulim F. 2007. Hepadnaviruses, p 2977-3029. In Knipe DM, Howley PM (ed), Fields virology, 5th ed. Lippincott Williams amp; Wilkins, Philadelphia, PA.
53. Singh AK, Swarnalatha M, Kumar V. 2011. c-ETS1 facilitates G1/S-phase transition by up-regulating cyclin E and CDK2 genes and cooperates with hepatitis B virus X protein for their deregulation. J. Biol. Chem. 286:21961-21970.
54. Soni R, et al. 2001. Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4. J. Natl. Cancer Inst. 93:436-446.
55. Summers J, Smith PM, Horwich AL. 1990. Hepadnavirus envelope proteins regulate covalently closed circular DNA amplification. J. Virol. 64:2819-2824.
56. Tanaka M, et al. 2004. Synthesis of anilino-monoindolylmaleimides as potent and selective PKCbeta inhibitors. Bioorg. Med. Chem. Lett. 14:5171-5174.
57. Toullec D, et al. 1991. The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J. Biol. Chem. 266:15771-15781.
58. Vassilev LT. 2006. Cell cycle synchronization at the G2/M phase border by reversible inhibition of CDK1. Cell Cycle 5:2555-2556.
59. Vassilev LT, et al. 2006. Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1. Proc. Natl. Acad. Sci. U. S. A. 103:10660-10665.
60. Vesely J, et al. 1994. Inhibition of cyclin-dependent kinases by purine analogues. Eur. J. Biochem. 224:771-786.
61. Wang X, Grammatikakis N, Hu J. 2002. Role of p50/CDC37 in hepadnavirus assembly and replication. J. Biol. Chem. 277:24361-24367.
62. Weigand K, Knaust A, Schaller H. 2010. Assembly and export determine the intracellular distribution of hepatitis B virus core protein subunits. J. Gen. Virol. 91:59-67.
63. Wingfield PT, Stahl SJ, Williams RW, Steven AC. 1995. Hepatitis core antigen produced in Escherichia coli: subunit composition, conformational analysis, and in vitro capsid assembly. Biochemistry 34:4919-4932.
64. Wittkop L, et al. 2010. Inhibition of protein kinase C phosphorylation of hepatitis B virus capsids inhibits virion formation and causes intracellular capsid accumulation. Cell Microbiol. 12:962-975.
65. Wynne SA, Crowther RA, Leslie AG. 1999. The crystal structure of the human hepatitis B virus capsid. Mol. Cell 3:771-780.
66. Yeh CT, Liaw YF, Ou JH. 1990. The arginine-rich domain of hepatitis B virus precore and core proteins contains a signal for nuclear transport. J. Virol. 64:6141-6147.
67. Yeh CT, Wong SW, Fung YK, Ou JH. 1993. Cell cycle regulation of nuclear localization of hepatitis B virus core protein. Proc. Natl. Acad. Sci. U. S. A. 90:6459-6463.
68. Yu M, Summers J. 1994. Phosphorylation of the duck hepatitis B virus capsid protein associated with conformational changes in the C terminus. J. Virol. 68:2965-2969.
69. Zandomeni RO. 1989. Kinetics of inhibition by 5,6-dichloro-1-beta-Dribofuranosylbenzimidazole on calf thymus casein kinase II. Biochem. J. 262:469-473.
70. Zheng Y, Fu XD, Ou JH. 2005. Suppression of hepatitis B virus replication by SRPK1 and SRPK2 via a pathway independent of the phosphorylation of the viral core protein. Virology 342:150-158.
71. Zlotnick A, et al. 1996. Dimorphism of hepatitis B virus capsids is strongly influenced by the C-terminus of the capsid protein. Biochemistry 35:7412-7421.